Indeed, recent studies have described that HDACIs induced the expression of TRAIL and TRAIL-receptors in leukaemia cells, breast and colon cancer cells [24-28], while other reports have shown no changes in the expression level of DR4, DR5 and DcR2 in melanoma and lymphoma cells [31,37]. This evidence concerns the gene TNFRSF10B and melanoma.